Exelixis, Inc. (EXEL) AI Stock Analysis

Exelixis, Inc. is an oncology-focused biotechnology company dedicated to the discovery, development, and commercialization of treatments for various cancers in the United States. Its primary commercial offerings include CABOMETYX tablets for advanced renal cell carcinoma and COMETRIQ capsules for progressive metastatic medullary thyroid cancer, both targeting key tyrosine kinases including MET, AXL, RET, and VEGF receptors. The company also markets COTELLIC for advanced melanoma and MINNEBRO for hypertension in Japan. Its development pipeline includes zanzalintinib, antibody-drug conjugate XB002, and CDK7 inhibitor XL102.

Exelixis increased annual revenue from $1.43B in FY2021 to $2.32B in FY2025, recording a 5-year revenue CAGR of 18.6%. Over this period, net income rose from $231.1M in FY2021 to $782.6M in FY2025, supported by stable gross margins that reached 96.4% in FY2025. Operating margin expanded from 20.0% in FY2021 to 37.6% in FY2025 as R&D expenses settled at $825.0M. For the trailing twelve months, revenue reached $2.44B with a net profit margin of 35.3% and diluted EPS of $3.17. In the latest quarter ended June 30, 2026, quarterly revenue grew 10.6% year-over-year while quarterly earnings expanded 26.2%.

As of June 30, 2026, Exelixis held $839.4M in cash and short-term investments against $165.9M in total debt, resulting in a net cash position of $673.5M. The company maintains a current ratio of 3.46 and a debt-to-equity ratio of 0.09 across $1.84B in shareholders' equity. In FY2025, operating cash flow stood at $884.3M and free cash flow reached $844.3M after capital expenditures of $39.9M. Exelixis directed $947.5M toward share buybacks in FY2025, contributing to a 19.7% reduction in share count over 5 years.

Exelixis trades at a trailing P/E of 19.6x and a forward P/E of 13.6x, compared to medians of 24.6x and 17.3x for its US-listed Healthcare peers. Its enterprise value of $13.38B represents an EV/EBITDA multiple of 13.1x, above the peer median of 12.0x, while its price-to-sales ratio of 6.3x exceeds the sector peer median of 4.1x. Over the past year, EXEL delivered a 58.7% return compared to 16.8% for the S&P 500 (SPY), and its 5-year return of 185.2% outperformed SPY's 83.0% gain.

Wall Street analysts hold 6 Strong Buy, 1 Buy, 10 Hold, and 1 Sell recommendations on Exelixis. The mean price target is $54.87, representing an 11.8% decline from the last closing price of $62.23. Consensus projections forecast EPS of $3.58 on revenue of $2.55B for the fiscal year ending December 31, 2026, followed by EPS of $4.27 on revenue of $2.90B in FY2027. Exelixis beat EPS estimates in each of the last 4 quarters, with its next earnings release scheduled for November 3, 2026.

This page is an AI-written research summary of Exelixis, Inc. (EXEL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: EXEL income statement, EXEL balance sheet, EXEL key metrics, EXEL analyst forecast, EXEL chart. See the EXEL stock overview for the latest quote and news.